ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 69 citations in OpenAlex.
- Advances in oncolytic virus delivery strategies and challenges in clinical translation.Materials today. Bio · 2026Review
- A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.Molecular therapy. Oncology · 2026Article
- Review
- Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.Molecular therapy. Oncology · 2024Review
- Applications of nuclear-based imaging in gene and cell therapy: probe considerations.Molecular therapy oncolytics · 2021Article
- Measles Virus as an Oncolytic Immunotherapy.Cancers · 2021Review
- Immunotherapy in Multiple Myeloma.Cells · 2020Review
- Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?Cancer cell international · 2020Review
- Syncytia Formation in Oncolytic Virotherapy.Molecular therapy oncolytics · 2019Review
- Oncolytic Viruses for Multiple Myeloma Therapy.Cancers · 2018Review
- Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading.Virologica Sinica · 2018Article
- Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.Blood cancer journal · 2017Review
- Designing and building oncolytic viruses.Future virology · 2017Review
- Potential and clinical translation of oncolytic measles viruses.Expert opinion on biological therapy · 2017Review
- Oncolytic Viral Therapy for Mesothelioma.Frontiers in oncology · 2017Review
- Potential of oncolytic viruses in the treatment of multiple myeloma.Oncolytic virotherapy · 2017Review
- Review
- Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Human gene therapy. Clinical development · 2016Article
- Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells.Clinical lymphoma, myeloma & leukemia · 2016Article
- A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.Molecular therapy oncolytics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Multiple myeloma (MM) is bone marrow plasma cell malignancy. A clinical trial utilizing intravenous administration of oncolytic measles virus (MV) encoding the human sodium-iodide symporter (MV-NIS) is ongoing in myeloma patients. However, intravenously administered MV-NIS is rapidly neutralized by antiviral antibodies. Because myeloma cell lines retain bone marrow tropism, they may be ideal as carriers for delivery of MV-NIS to myeloma deposits. A disseminated human myeloma (KAS 6/1) model was established. Biodistribution of MM1, a myeloma cell line, was determined after intravenous infusion. MM1 cells were found in the spine, femurs, and mandibles of tumor-bearing mice. Lethally irradiated MM1 cells remained susceptible to measles infection and transferred MV to KAS 6/1 cells in the presence of measles immune sera. Mice-bearing disseminated myeloma and passively immunized with measles immune serum were given MV-NIS or lethally irradiated MV-NIS-infected MM1 carriers. The antitumor activity of MV-NIS was evident only in measles naive mice and not in passively immunized mice. In contrast, survivals of both measles naive and immune mice were extended using MV-NIS-infected MM1 cell carriers. Hence, we demonstrate for the first time that systemically administered cells can serve as MV carriers and prolonged survival of mice with pre-existing antimeasles antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.